KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Other financing activities (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Other financing activities data on record, last reported at -$3.1 million in Q4 2025.

  • For Q4 2025, Other financing activities fell 3200.0% year-over-year to -$3.1 million; the TTM value through Dec 2025 reached -$3.8 million, down 22.58%, while the annual FY2025 figure was -$3.8 million, 22.58% down from the prior year.
  • Other financing activities reached -$3.1 million in Q4 2025 per EW's latest filing, down from -$2.4 million in the prior quarter.
  • Across five years, Other financing activities topped out at $7.2 million in Q2 2024 and bottomed at -$10.2 million in Q3 2024.
  • Average Other financing activities over 5 years is -$647368.4, with a median of -$100000.0 recorded in 2021.
  • Peak YoY movement for Other financing activities: skyrocketed 1900.0% in 2023, then plummeted 3200.0% in 2025.
  • A 5-year view of Other financing activities shows it stood at $700000.0 in 2021, then tumbled by 85.71% to $100000.0 in 2022, then surged by 1900.0% to $2.0 million in 2023, then crashed by 95.0% to $100000.0 in 2024, then tumbled by 3200.0% to -$3.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were -$3.1 million in Q4 2025, -$2.4 million in Q3 2025, and $1.0 million in Q2 2025.